Abstract:14 of those (77.8%) maintained an eliciting dose of > _1000 mg at month 38. Local patch-site skin reactions were common but decreased over time. There was no treatment-related epinephrine use in years 2 or 3. Compliance was high (96.9%), and withdrawals due to treatment-related adverse events were low (1%). Conclusions: These results demonstrate that daily EPIT treatment for peanut allergy beyond 1 year leads to continued response from a well-tolerated, simple-to-use regimen. (J
“…Epicutaneous immunotherapy involves the administration of the allergen by means of a skin patch. The clinical evidence shows efficacy for epicutaneous immunotherapy as it increases the oral threshold dose in provocation testing after a treatment phase of several months with very good tolerability [31]. A recently published phase-2 placebo-controlled dosefinding study showed statistically significant results with a 10-fold increase in dose in 48% of patients receiving epicutaneous therapy with a patch containing 250 µg peanut protein [29].…”
“…The specific forms of treatment can also be differentiated on the basis of route of administration. Numerous studies have been published to date on epicutaneous, sublingual, as well as oral immunotherapy (Table 1; [18][19][20][21][22][23][24][25][26][27][28][29][30][31][32][33][34][35]) and are discussed below.…”
Peanut allergy is a potentially life-threatening disease because it leads to severe allergic reactions, especially in children but also in adults. So far, allergen avoidance is the most effective therapy for treating peanut allergy. In this article, current developments of peanut allergy specific immunotherapy are critically discussed based on the existing literature. These include sublingual, epicutaneous and oral peanut immunotherapy. Nonspecific treatment approaches with new-targeted antibodies such as anti-IgE (omalizumab) or anti-IL-4/IL-13 receptor antibodies (dupilumab) can also be used to treat peanut allergy with regard to the mode of action of these antibodies. Multiple studies are already available for omalizumab and are currently performed with dupilumab. Whether and which therapies for the treatment of peanut allergy will be available on the market in the future is not only relevant in terms of clinical effectiveness in the sense of a long-term stable increase in the threshold level, but also in terms of the tolerability in everyday life of affected patients.
“…Epicutaneous immunotherapy involves the administration of the allergen by means of a skin patch. The clinical evidence shows efficacy for epicutaneous immunotherapy as it increases the oral threshold dose in provocation testing after a treatment phase of several months with very good tolerability [31]. A recently published phase-2 placebo-controlled dosefinding study showed statistically significant results with a 10-fold increase in dose in 48% of patients receiving epicutaneous therapy with a patch containing 250 µg peanut protein [29].…”
“…The specific forms of treatment can also be differentiated on the basis of route of administration. Numerous studies have been published to date on epicutaneous, sublingual, as well as oral immunotherapy (Table 1; [18][19][20][21][22][23][24][25][26][27][28][29][30][31][32][33][34][35]) and are discussed below.…”
Peanut allergy is a potentially life-threatening disease because it leads to severe allergic reactions, especially in children but also in adults. So far, allergen avoidance is the most effective therapy for treating peanut allergy. In this article, current developments of peanut allergy specific immunotherapy are critically discussed based on the existing literature. These include sublingual, epicutaneous and oral peanut immunotherapy. Nonspecific treatment approaches with new-targeted antibodies such as anti-IgE (omalizumab) or anti-IL-4/IL-13 receptor antibodies (dupilumab) can also be used to treat peanut allergy with regard to the mode of action of these antibodies. Multiple studies are already available for omalizumab and are currently performed with dupilumab. Whether and which therapies for the treatment of peanut allergy will be available on the market in the future is not only relevant in terms of clinical effectiveness in the sense of a long-term stable increase in the threshold level, but also in terms of the tolerability in everyday life of affected patients.
“…2 ). Enfin, deux études sur l’allergie à l’arachide apportent des résultats intéressants, celle de Kim et al [55] qui démontre clairement le bénéfice au long cours d’une désensibilisation par voie sublinguale, et celle de Fleicher et al [56] qui montre l’intérêt de la voie épicutanée avec le même allergène. Fig.…”
Section: Principales Indications En Pédiatrieunclassified
L’immunothérapie spécifique allergénique nécessite l’administration répétée d’allergènes dans le but de provoquer une tolérance clinique et immunologique. C’est la seule thérapeutique à visée étiologique qui permet de modifier l’évolution de la maladie en assurant une rémission après l’interruption de la procédure. La prévention de nouvelles sensibilisations par l’immunothérapie reste discutée. Nous envisagerons dans cette revue les principaux mécanismes immunologiques et les indications de l’immunothérapie chez l’enfant et l’adolescent.
“…40 A recently published follow up report of longer-term EPIT (involving an additional 2 years of treatment after reaching maintenance) in peanut-allergic children demonstrated sustained clinical benefit with high compliance and low discontinuation rates due to adverse events. 41 For the multi-allergic child, the simultaneous oral administration of a combination of food allergens compared with the administration of a single allergen has been studied. Multifood OIT in small phase I trials is shown to be comparable in safety to single-food immunotherapy.…”
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
